In recent years a new type of drug, called a “biologic,” has become increasingly common. Biologics are drugs that are manufactured by growing them inside living organisms (usually engineered cells), collecting them, and then injecting/infusing them into patients. Biologics are the fastest growing class of drug in the world and are providing new treatments for diseases, many of which previously had no treatments whatsoever.
One hope has been to implant the engineered cells that produce biologics directly into patients’ bodies. Diabetics would receive cells producing insulin, Fabry patients would get cells that produce a-gal A, people who are lactose intolerant would receive cells for lactase; the list goes on and on.
The problem has been our immune system. It doesn’t understand that these cells are there to help - it just sees a foreign invader and attacks them. Cell encapsulation solves that problem by protecting the cells from your immune system while still allowing interaction with the rest of your body. The technology to do this has been in development for a while now, and it’s about to become a reality.
CapCell Biologics is positioned to be at the forefront of this breakthrough. We’re currently engineering cells for patients with Fabry disease, a rare enzyme deficiency that’s currently treated with hours-long infusions every 2 weeks. We’re also in talks with NASA to use their technology to make the capsules.
There’s lots of potential with this method. Any disease that requires regular infusions (such as Crohn’s, colitis, and diabetes) could be treated with cell encapsulation. Additional diseases that could be treated include Parkinson’s, other enzyme deficiencies like Gaucher and Pompe disease, and even cancer.
For a first-hand look at how NASA is planning to use this technology, view the video to the right. It features the inventor of the capsule technology, Dr. David Loftus of Ames Research Center in California.
CapCell Biologics is a patient-focused company. We believe patients shouldn’t be forced to pay exorbitant bills, receive partial-doses, or be move to new countries to receive treatment. These are complex issues and CapCell is taking steps now to address them.
We plan to begin pre-clinical research by 2020, which means it’s still early days. Sign up below for updates on our progress, or contact us using the information to the right if you’d like to speak with us directly.
Check back often as the site will be regularly updated in the coming weeks and months.
➤ Ben Young - CEO
➤ Jon Zaikowski - President
CapCell Biologics, Inc.
232 Meserole St #20
New York, NY, 11206
Stay up to date
Use the form below to sign up for news and updates from CapCell Biologics.